Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Yanshuo Cao"'
Autor:
Xiaoyi Chong, Yelizhati Madeti, Jieyuan Cai, Wenfei Li, Lin Cong, Jialin Lu, Liyang Mo, Huizhen Liu, Siyi He, Chao Yu, Zhiruo Zhou, Boya Wang, Yanshuo Cao, Zhenghang Wang, Lin Shen, Yakun Wang, Xiaotian Zhang
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-61 (2024)
Abstract The past few decades have witnessed the rise of immunotherapy for Gastrointestinal (GI) tract cancers. The role of immune checkpoint inhibitors (ICIs), particularly programmed death protein 1 (PD-1) and PD ligand-1 antibodies, has become inc
Externí odkaz:
https://doaj.org/article/c4cb46edf53244dcb7cbbf517944be03
Autor:
Yanni Wang, Chang Liu, Huan Chen, Xi Jiao, Yujiao Wang, Yanshuo Cao, Jian Li, Xiaotian Zhang, Yu Sun, Na Zhuo, Fengxiao Dong, Mengting Gao, Fengyuan Wang, Liyuan Dong, Jifang Gong, Tianqi Sun, Wei Zhu, Henghui Zhang, Lin Shen, Zhihao Lu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-11 (2024)
Abstract Epidermal growth factor receptor (EGFR) is reportedly overexpressed in most esophageal squamous cell carcinoma (ESCC) patients, but anti-EGFR treatments offer limited survival benefits. Our preclinical data showed the promising antitumor act
Externí odkaz:
https://doaj.org/article/e2fbea8821794ba987fb1ed31eebb222
Autor:
Keren Jia, Yang Chen, Yi Xie, Xicheng Wang, Yajie Hu, Yu Sun, Yanshuo Cao, Liyan Zhang, Yakun Wang, Zhenghang Wang, Zhihao Lu, Jian Li, Xiaotian Zhang, Lin Shen
Publikováno v:
The Innovation, Vol 5, Iss 2, Pp 100561- (2024)
Helicobacter pylori infection is associated with the risk of gastrointestinal (GI) cancers; however, its impact on immunotherapy for GI cancers remains uncertain. In this study, we included 10,122 patients who underwent 13C-urea breath tests. Among 6
Externí odkaz:
https://doaj.org/article/59bd499a7177470a99717ea7376bfb05
Autor:
Lin Shen, Ying Hu, Chang Liu, Jian Li, Henghui Zhang, Xueying Wu, Yanni Wang, Zhihao Lu, Mengting Gao, Xi Jiao, Na Zhuo, Fengxiao Dong, Yujiao Wang, Fengyuan Wang, Yanshuo Cao
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background Immune checkpoint inhibitors (ICIs) have significantly improved patient survival in multiple cancers. However, therapy response in esophageal cancer is limited to subgroups of patients and clinically useful predictive biomarkers are lackin
Externí odkaz:
https://doaj.org/article/6a12684a88b9404189ebb7667182f04a
Autor:
Yakun Wang, Jifang Gong, Airong Wang, Jia Wei, Zhi Peng, Xicheng Wang, Jun Zhou, Changsong Qi, Dan Liu, Jian Li, Ming Lu, Zhihao Lu, Yanshuo Cao, Jiajia Yuan, Ruyan Zhang, Jianmin Fang, Xiaotian Zhang, Lin Shen
Publikováno v:
EClinicalMedicine, Vol 68, Iss , Pp 102415- (2024)
Summary: Background: Although the antibody–drug conjugates (ADCs) have significantly improved the survival outcomes of patients with human epidermal receptor 2 (HER2)-expressing gastric or gastroesophageal junction (G/GEJ) cancer, the efficacy of A
Externí odkaz:
https://doaj.org/article/5dc54445ecf6486e99c3750ccb823bcd
Autor:
Dan Liu, Furong Kou, Jifang Gong, Zhiqiang Wang, Xiaotian Zhang, Jian Li, Yan Li, Jie Li, Jun Zhou, Ming Lu, Xicheng Wang, Zhihao Lu, Yanshuo Cao, Jianjun Zou, Xiaoyu Zhu, Ruihua Xu, Lin Shen
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10704-10714 (2023)
Abstract Aim Pyrotinib (an irreversible pan‐ErbB small‐molecular tyrosine kinase inhibitor) was approved in human epidermal growth factor receptor 2 (HER2)‐positive breast cancer and showed great antitumor activity in preclinical studies of gas
Externí odkaz:
https://doaj.org/article/63e320f911764ac5aff79f726b7be149
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundWe investigated the clinical and endoscopic features, management strategies, and outcomes of Chinese cancer patients with immune checkpoint inhibitor (ICI)-induced colitis.MethodThis single-centre retrospective study included patients who d
Externí odkaz:
https://doaj.org/article/3a5a7c7888974e8ba7a063b0227d65e3
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
An increased incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has been reported in many countries. However, the prevalence and impact factors of psychological distress and resilience in patients with GEP-NETs are unclear. We recru
Externí odkaz:
https://doaj.org/article/829c4862f8f946f692a1089d1956c203
Autor:
Qi Zhang, Ting Deng, Fen Yang, Weijian Guo, Dan Liu, Jiajia Yuan, Changsong Qi, Yanshuo Cao, Qiuqiong Yu, Huiming Cai, Zhi Peng, Xicheng Wang, Jun Zhou, Ming Lu, Jifang Gong, Jian Li, Yi Ba, Lin Shen
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Simmitecan is a potent inhibitor of topoisomerase I with anti-tumor activity. This phase Ib trial was conducted to investigate the safety and anti-tumor effect of simmitecan alone or in combination with other drugs.Methods: Eligible patie
Externí odkaz:
https://doaj.org/article/a4f6177649dd43ff8061081df32f3c47
Autor:
Dan Liu, Furong Kou, Jifang Gong, Zhiqiang Wang, Xiaotian Zhang, Jian Li, Yan Li, Jie Li, Jun Zhou, Ming Lu, Xicheng Wang, Zhihao Lu, Yanshuo Cao, Jianjun Zou, Xiaoyu Zhu, Ruihua Xu, Lin Shen
Publikováno v:
Cancer Medicine. 12:10704-10714
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::467d3c656466e3d02d33da6ae83d97c8
https://doi.org/10.1002/cam4.5830
https://doi.org/10.1002/cam4.5830